Related Experiment Video
Updated: Jan 6, 2026

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
Published on: July 15, 2014
The spectrum of neuromuscular diseases with tubular aggregates
Hebatallah R Rashed1, Duygu Selcen2
1Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Ain Shams University, Cairo, Egypt.
Abstract:
Tubular aggregates are granular inclusions of unclear function postulated to be massive proliferations from lateral sacs of the sarcoplasmic reticulum. However, immunohistochemical studies suggest a more complex origin. They usually accumulate in type 2 fibers and do not react to the mitochondrial oxidative enzymes. Tubular aggregates are present in diverse acquired and inherited clinical conditions. Myopathies in which the predominant pathological hallmark is tubular aggregates usually manifest in one of three major phenotypes: 1) slowly progressive, proximal predominant weakness; 2) myalgia with or without stiffness and cramps; 3) limb-girdle myasthenic syndrome. Muscle biopsy may play an indispensable role in diagnosing these conditions. Mutations in STIM1 and ORAI1 proteins cause tubular aggregate myopathies (TAM) and Stormorken syndrome (STRMK). These proteins are the main players in store-operated Ca2+ entry (SOCE) mechanism, a major regulator of Ca2+ homeostasis. Other regulators of SOCE include calsequestrin, ALG2, ALG14, DPAGT1, and GFPT1. Their dysfunction impacts Ca2+ homeostasis and causes conditions overlapping with TAM/STRMK at the clinical and histological level.
Related Concept Videos
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Satellite Stem Cells and Muscular Dystrophy
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

